Review



inos antibody - bsa free  (Bio-Techne corporation)


Bioz Verified Symbol Bio-Techne corporation is a verified supplier
Bioz Manufacturer Symbol Bio-Techne corporation manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Bio-Techne corporation inos antibody - bsa free
    Inos Antibody Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 161 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inos antibody - bsa free/product/Bio-Techne corporation
    Average 95 stars, based on 161 article reviews
    inos antibody - bsa free - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    inos antibody - bsa free  (Bio-Techne corporation)
    95
    Bio-Techne corporation inos antibody - bsa free
    Inos Antibody Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inos antibody - bsa free/product/Bio-Techne corporation
    Average 95 stars, based on 1 article reviews
    inos antibody - bsa free - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    inos nb300-605 antibody  (Novus Biologicals)
    90
    Novus Biologicals inos nb300-605 antibody
    CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of <t>iNOs,</t> <t>and</t> <t>ARG1</t> at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.
    Inos Nb300 605 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inos nb300-605 antibody/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    inos nb300-605 antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    inos antibody nb300-605  (Novus Biologicals)
    90
    Novus Biologicals inos antibody nb300-605
    CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of <t>iNOs,</t> <t>and</t> <t>ARG1</t> at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.
    Inos Antibody Nb300 605, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inos antibody nb300-605/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    inos antibody nb300-605 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti-inos nb300-605  (Novus Biologicals)
    90
    Novus Biologicals anti-inos nb300-605
    CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of <t>iNOs,</t> <t>and</t> <t>ARG1</t> at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.
    Anti Inos Nb300 605, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-inos nb300-605/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    anti-inos nb300-605 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    primary antibody against inducible nitric oxide synthase (inos) nb300–605  (Novus Biologicals)
    90
    Novus Biologicals primary antibody against inducible nitric oxide synthase (inos) nb300–605
    CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of <t>iNOs,</t> <t>and</t> <t>ARG1</t> at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.
    Primary Antibody Against Inducible Nitric Oxide Synthase (Inos) Nb300–605, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against inducible nitric oxide synthase (inos) nb300–605/product/Novus Biologicals
    Average 90 stars, based on 1 article reviews
    primary antibody against inducible nitric oxide synthase (inos) nb300–605 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of iNOs, and ARG1 at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.

    Journal: Bioactive Materials

    Article Title: One-step strategy for fabricating icariin-encapsulated biomimetic Scaffold: Orchestrating immune, angiogenic, and osteogenic cascade for enhanced bone regeneration

    doi: 10.1016/j.bioactmat.2025.06.001

    Figure Lengend Snippet: CHP@IC directs macrophage M2 polarization to regulate the immune microenvironment. (A–C) The FDA/PI staining, phalloidin staining, CCK8 result, and cell spread area of Raw264.7 cultured on the surface of CHP and CHP@IC scaffolds. (D) The RT-qPCR results of macrophage phenotypic transition at 5 days. (E)The WB results and the relative protein expression of iNOs, and ARG1 at 5 days. (F) The FC result of CD86 and CD206 at 5 days. (G) The IF staining of iNOs and CD206 at 5 days. (H) Quantitative analysis of iNOs, and CD206 fluorescent intensity (n = 3). (I) The RT-qPCR results of the cytokine in immune microenvironment at 5 days. (J) ELISA results of the cytokine at 5 days. (I) Schematic representation of the CHP@IC-mediated shift in the immune microenvironment.

    Article Snippet: Then, the membrane was blocked with 5 % skimmed milk and incubated with iNOs (NB300-605, Novus, USA), ARG1 (16001-1-AP, Proteintech, UK), STAT3 (ET1607-38, HUABIO, China), phospho-STAT3 antibodies (S727) (ET1607-39, HUABIO, China) and GAPDH (ab8245, Abcam, UK) overnight.

    Techniques: Staining, Cell Culture, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay

    CHP@IC activates the STAT3 signaling pathway. (A) Schematic representation of CHP@IC activation of the STAT3 signaling pathway. (B–C) The WB results and the relative protein expression of STAT3, p-STAT3 and p-STAT3/STAT3 treated with CHP@IC scaffold. (D) The WB results of STAT3, p-STAT3 and p-STAT3/STAT3 treated with/without NSC 74859. (E) The WB results of iNOs and ARG1 treated with/without NSC 74859. (F)The quantitative analysis of protein expression with/without NSC 74859. (G–H) The RT-qPCR results of macrophages treated with/without NSC 74859.

    Journal: Bioactive Materials

    Article Title: One-step strategy for fabricating icariin-encapsulated biomimetic Scaffold: Orchestrating immune, angiogenic, and osteogenic cascade for enhanced bone regeneration

    doi: 10.1016/j.bioactmat.2025.06.001

    Figure Lengend Snippet: CHP@IC activates the STAT3 signaling pathway. (A) Schematic representation of CHP@IC activation of the STAT3 signaling pathway. (B–C) The WB results and the relative protein expression of STAT3, p-STAT3 and p-STAT3/STAT3 treated with CHP@IC scaffold. (D) The WB results of STAT3, p-STAT3 and p-STAT3/STAT3 treated with/without NSC 74859. (E) The WB results of iNOs and ARG1 treated with/without NSC 74859. (F)The quantitative analysis of protein expression with/without NSC 74859. (G–H) The RT-qPCR results of macrophages treated with/without NSC 74859.

    Article Snippet: Then, the membrane was blocked with 5 % skimmed milk and incubated with iNOs (NB300-605, Novus, USA), ARG1 (16001-1-AP, Proteintech, UK), STAT3 (ET1607-38, HUABIO, China), phospho-STAT3 antibodies (S727) (ET1607-39, HUABIO, China) and GAPDH (ab8245, Abcam, UK) overnight.

    Techniques: Activation Assay, Expressing, Quantitative RT-PCR